17β-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma

Katalin Prokai-Tatrai, Hua Xin, Vien Nguyen, Szabolcs Szarka, Balazs Blazics, Laszlo Prokai, Peter Koulen

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Neuroprotection in glaucoma as a curative strategy complementary to current therapies to lower intraocular pressure (IOP) is highly desirable. This study was designed to investigate neuroprotection by 17β-estradiol (E2) to prevent retinal ganglion cell (RGC) death in a glaucoma model of surgically elevated IOP in rats. We found that daily treatment with E2-containing eye drops resulted in significant E2 concentration in the retina with concomitant profound neuroprotective therapeutic benefits, even in the presence of continually elevated IOP. The number of apoptotic cells in the RGC layer was significantly decreased in the E2-treated group, when compared to the vehicle-treated controls. Deterioration in visual acuity in these animals was also markedly prevented. Using mass spectrometry-based proteomics, beneficial changes in the expression of several proteins implicated in the maintenance of retinal health were also found in the retina of E2-treated animals. On the other hand, systemic side effects could not be avoided with the eye drops, as confirmed by the measured high circulating estrogen levels and through the assessment of the uterus representing a typical hormone-sensitive peripheral organ. Collectively, the demonstrated significant neuroprotective effect of topical E2 in the selected animal model of glaucoma provides a clear rationale for further studies aiming at targeting E2 into the eye while avoiding systemic E2 exposure to diminish undesirable off-target side effects.

Original languageEnglish
Pages (from-to)3253-3261
Number of pages9
JournalMolecular Pharmaceutics
Volume10
Issue number8
DOIs
StatePublished - 5 Aug 2013

Fingerprint

Retinal Ganglion Cells
Ophthalmic Solutions
Intraocular Pressure
Glaucoma
Estradiol
Retina
Neuroprotective Agents
Proteomics
Visual Acuity
Uterus
Mass Spectrometry
Estrogens
Cell Death
Therapeutics
Animal Models
Cell Count
Hormones
Health
Proteins
Neuroprotection

Keywords

  • 17β-estradiol
  • LC-MS/MS
  • contrast sensitivity
  • estrogen quantitation
  • eye drop
  • glaucomatous retinopathy
  • neuroprotection
  • rat model
  • retina proteomics
  • visual acuity

Cite this

Prokai-Tatrai, Katalin ; Xin, Hua ; Nguyen, Vien ; Szarka, Szabolcs ; Blazics, Balazs ; Prokai, Laszlo ; Koulen, Peter. / 17β-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma. In: Molecular Pharmaceutics. 2013 ; Vol. 10, No. 8. pp. 3253-3261.
@article{c62d4db1d7cc4c188acd3b41554d73d7,
title = "17β-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma",
abstract = "Neuroprotection in glaucoma as a curative strategy complementary to current therapies to lower intraocular pressure (IOP) is highly desirable. This study was designed to investigate neuroprotection by 17β-estradiol (E2) to prevent retinal ganglion cell (RGC) death in a glaucoma model of surgically elevated IOP in rats. We found that daily treatment with E2-containing eye drops resulted in significant E2 concentration in the retina with concomitant profound neuroprotective therapeutic benefits, even in the presence of continually elevated IOP. The number of apoptotic cells in the RGC layer was significantly decreased in the E2-treated group, when compared to the vehicle-treated controls. Deterioration in visual acuity in these animals was also markedly prevented. Using mass spectrometry-based proteomics, beneficial changes in the expression of several proteins implicated in the maintenance of retinal health were also found in the retina of E2-treated animals. On the other hand, systemic side effects could not be avoided with the eye drops, as confirmed by the measured high circulating estrogen levels and through the assessment of the uterus representing a typical hormone-sensitive peripheral organ. Collectively, the demonstrated significant neuroprotective effect of topical E2 in the selected animal model of glaucoma provides a clear rationale for further studies aiming at targeting E2 into the eye while avoiding systemic E2 exposure to diminish undesirable off-target side effects.",
keywords = "17β-estradiol, LC-MS/MS, contrast sensitivity, estrogen quantitation, eye drop, glaucomatous retinopathy, neuroprotection, rat model, retina proteomics, visual acuity",
author = "Katalin Prokai-Tatrai and Hua Xin and Vien Nguyen and Szabolcs Szarka and Balazs Blazics and Laszlo Prokai and Peter Koulen",
year = "2013",
month = "8",
day = "5",
doi = "10.1021/mp400313u",
language = "English",
volume = "10",
pages = "3253--3261",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "8",

}

17β-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma. / Prokai-Tatrai, Katalin; Xin, Hua; Nguyen, Vien; Szarka, Szabolcs; Blazics, Balazs; Prokai, Laszlo; Koulen, Peter.

In: Molecular Pharmaceutics, Vol. 10, No. 8, 05.08.2013, p. 3253-3261.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 17β-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma

AU - Prokai-Tatrai, Katalin

AU - Xin, Hua

AU - Nguyen, Vien

AU - Szarka, Szabolcs

AU - Blazics, Balazs

AU - Prokai, Laszlo

AU - Koulen, Peter

PY - 2013/8/5

Y1 - 2013/8/5

N2 - Neuroprotection in glaucoma as a curative strategy complementary to current therapies to lower intraocular pressure (IOP) is highly desirable. This study was designed to investigate neuroprotection by 17β-estradiol (E2) to prevent retinal ganglion cell (RGC) death in a glaucoma model of surgically elevated IOP in rats. We found that daily treatment with E2-containing eye drops resulted in significant E2 concentration in the retina with concomitant profound neuroprotective therapeutic benefits, even in the presence of continually elevated IOP. The number of apoptotic cells in the RGC layer was significantly decreased in the E2-treated group, when compared to the vehicle-treated controls. Deterioration in visual acuity in these animals was also markedly prevented. Using mass spectrometry-based proteomics, beneficial changes in the expression of several proteins implicated in the maintenance of retinal health were also found in the retina of E2-treated animals. On the other hand, systemic side effects could not be avoided with the eye drops, as confirmed by the measured high circulating estrogen levels and through the assessment of the uterus representing a typical hormone-sensitive peripheral organ. Collectively, the demonstrated significant neuroprotective effect of topical E2 in the selected animal model of glaucoma provides a clear rationale for further studies aiming at targeting E2 into the eye while avoiding systemic E2 exposure to diminish undesirable off-target side effects.

AB - Neuroprotection in glaucoma as a curative strategy complementary to current therapies to lower intraocular pressure (IOP) is highly desirable. This study was designed to investigate neuroprotection by 17β-estradiol (E2) to prevent retinal ganglion cell (RGC) death in a glaucoma model of surgically elevated IOP in rats. We found that daily treatment with E2-containing eye drops resulted in significant E2 concentration in the retina with concomitant profound neuroprotective therapeutic benefits, even in the presence of continually elevated IOP. The number of apoptotic cells in the RGC layer was significantly decreased in the E2-treated group, when compared to the vehicle-treated controls. Deterioration in visual acuity in these animals was also markedly prevented. Using mass spectrometry-based proteomics, beneficial changes in the expression of several proteins implicated in the maintenance of retinal health were also found in the retina of E2-treated animals. On the other hand, systemic side effects could not be avoided with the eye drops, as confirmed by the measured high circulating estrogen levels and through the assessment of the uterus representing a typical hormone-sensitive peripheral organ. Collectively, the demonstrated significant neuroprotective effect of topical E2 in the selected animal model of glaucoma provides a clear rationale for further studies aiming at targeting E2 into the eye while avoiding systemic E2 exposure to diminish undesirable off-target side effects.

KW - 17β-estradiol

KW - LC-MS/MS

KW - contrast sensitivity

KW - estrogen quantitation

KW - eye drop

KW - glaucomatous retinopathy

KW - neuroprotection

KW - rat model

KW - retina proteomics

KW - visual acuity

UR - http://www.scopus.com/inward/record.url?scp=84881323172&partnerID=8YFLogxK

U2 - 10.1021/mp400313u

DO - 10.1021/mp400313u

M3 - Article

C2 - 23841874

AN - SCOPUS:84881323172

VL - 10

SP - 3253

EP - 3261

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 8

ER -